Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat [Yahoo! Finance]
Certara, Inc. (CERT)
Company Research
Source: Yahoo! Finance
RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to $135 million. The transaction is expected to close during the second quarter of 2026 subject to customary closing conditions. “Certara's strategy is centered on expanding the scale, reach, and impact of our MIDD and Clinical Intelligence solutions,” said Jon Resnick, Chief Executive Officer. “This transaction underlines our commitment to the acceleration of AI-integrated modeling and simulation across the drug development lifecycle.” In 2025, the Regulatory and Medical Writing business generated $50 million in revenue and $17 million in adjusted EBITDA, excluding unallocated overhead expense. The Regulatory and Medical Writing business includes approximately 220 employees. “This transaction enhan
Show less
Read more
Impact Snapshot
Event Time:
CERT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERT alerts
High impacting Certara, Inc. news events
Weekly update
A roundup of the hottest topics
CERT
News
- AI in Predictive Toxicology Research Report 2026 Featuring Certara, Schrodinger, Instem, Simulations Plus, Lhasa, Chemaxon - Global Forecast to 2030 and 2035 [Yahoo! Finance]Yahoo! Finance
- Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- How The Certara (CERT) Story Is Shifting As Analysts Recut Targets And Expectations [Yahoo! Finance]Yahoo! Finance
- Certara: An Interesting Situation To Keep Track Off [Seeking Alpha]Seeking Alpha
- Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to VeristatGlobeNewswire
CERT
Earnings
- 2/26/26 - Beat
CERT
Sec Filings
- 4/28/26 - Form D
- 4/22/26 - Form 8-K
- 4/6/26 - Form SCHEDULE
- CERT's page on the SEC website